Nine-month results 2022 of Sartorius Stedim Biotech
prnewswire.com
news
2022-10-19 05:00:00

Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent
Overall market situation characterized by innovations and strong growth drivers; current development as expected influenced by swift normalization of demand
Outlook for 2022 specified: Sales revenue growth now expected to be in the lower half of the previous range of 15 to 19 percent; projection for underlying EBITDA margin unchanged at more than 35 percent
Uncertainties due to the global political and economic situation currently remain high

AUBAGNE, France, Oct.
